Domestic Digital Therapeutics Expected to Fully Spread Around 2025
Yano Research Institute (the President, Takashi Mizukoshi) carried out the domestic digital therapeutics (DTx) market, and found out the current status, challenges, trends of market players, and future outlook.
Summary of Research Findings
Digital therapeutics (hereafter called as “DTx”) is one of those medical equipment programs that use digital technologies to deliver medical interventions of treating, managing, and preventing a broad spectrum of diseases and disorders and is operated by the patients.
In Japan, the development of DTx has started in around 2015. In December 2020, Japan’s first DTx was launched, which was for the patients of nicotine dependence. Since 2019, the development of DTx has become vigorous as pharmaceutical companies began entering the market by cooperating with some companies from inside and outside the countries developing DTx, which attracted more attention. After 2021, various DTx are likely to be launched one after another, and are projected to be well accepted by around 2025.
Diversification of Companies Entering DTx Market Expected
The players of the domestic DTx market are expected to diversify, as DTx developing enterprises as well as pharmaceutical companies enter the market by cooperating with domestic and overseas DTx companies, while some companies developing general healthcare apps start developing DTx apps from their in-house apps. In addition, life insurance companies and the manufacturers of medical information systems or medical equipment, and various other companies are likely to enter and invigorate the market.
The copyright and all other rights pertaining to this report belong to Yano Research Institute.
Please contact our PR team when quoting the report contents for the purpose other than media coverage.
Depending on the purpose of using our report, we may ask you to present your sentences for confirmation beforehand.